The North America IVD (In Vitro Diagnostic) Reagents Market is poised for significant growth over the next decade. In 2025, the market is valued at USD 8,460 million and is expected to reach USD 17,950 million by 2035, at a CAGR of 7.5% from 2024 to 2035. The market is bolstered by technological advancements, the increasing burden of chronic diseases, the rising demand for personalized medicine, and ongoing expansion in point-of-care diagnostics.
The economic impact of tariffs on "North America IVD Reagents Market".
Market Growth Drivers
Rising Prevalence of Chronic and Infectious Diseases: The increasing incidence of chronic diseases such as diabetes, cancer, and cardiovascular disorders—alongside infectious diseases—has accelerated the demand for IVD reagents. For instance, Roche Diagnostics has expanded its range of reagents to address growing diagnostic needs, leading to improved patient outcomes and a larger consumer base.
Technological Advancements and Product Launches: Continuous innovation in IVD technologies, including automation, digital PCR, and next-generation sequencing, is driving market expansion. Abbott Laboratories has introduced a new line of highly sensitive IVD reagents, allowing for faster and more accurate disease diagnostics, further fueling market growth.
Market Trends
Growing Adoption of Point-of-Care Testing: There is a marked shift towards decentralized healthcare, with increased adoption of point-of-care testing (POCT) solutions. Companies like Quidel Corporation are leading the way, offering innovative reagents that enable rapid diagnostics outside traditional laboratory settings, thus facilitating quicker clinical decisions.
Integration of Artificial Intelligence in Diagnostics: AI-driven diagnostics are gaining traction, increasing the accuracy and efficiency of IVD reagent-based tests. Becton Dickinson (BD) has partnered with technology firms to integrate AI into its diagnostic platforms, optimizing reagent utilization and improving interpretive analytics in laboratory and clinical environments.
Market Opportunities
Expansion into Molecular Diagnostics: With the surge in demand for molecular diagnostic techniques, especially post-COVID-19, manufacturers like Thermo Fisher Scientific are investing in developing innovative molecular reagent kits to capture new market segments.
Emergence of Personalized Medicine: The trend towards personalized medicine opens up substantial opportunities for tailored IVD reagents. Companies such as Bio-Rad Laboratories are developing reagents suited for individualized disease profiling, enabling targeted therapies and improved patient management.
North America IVD Reagents Market Revenue Forecast (USD Million), 2020-2035
The chart illustrates sustained growth in the North America IVD Reagents Market between 2020 and 2035. The market revenue rises steadily from USD 5,200 million in 2020 to USD 8,460 million in 2025. It continues this growth trajectory, increasing to USD 12,400 million by 2030 and reaching a projected USD 17,950 million by 2035. This upward trend is attributed to higher test volumes, technological innovations, and expanding application areas, reflecting robust demand for IVD reagents across North America.
North America IVD Reagents Market Share by Region, 2025
The pie chart depicts the regional distribution of the North America IVD Reagents Market in 2025. The United States holds the largest market share at 77%, attributed to its advanced healthcare infrastructure and high adoption rates of diagnostic technologies. Canada follows with a 15% share, driven by growing healthcare expenditure and awareness. Mexico accounts for 6%, benefiting from evolving laboratory capabilities. The remaining 2% comprises other minor regional markets. This distribution highlights the dominance of the US while showcasing emerging opportunities in Canada and Mexico.
Recent Market Developments
In March 2024, Roche Diagnostics announced the launch of a new multiplex PCR-based IVD reagent specifically designed for rapid detection of respiratory pathogens, enhancing laboratory workflow efficiency and diagnostic accuracy in North America.
In May 2024, Abbott Laboratories received FDA approval for its newly-developed, high-sensitivity cardiovascular biomarker reagent, reinforcing its leadership in cardiac diagnostics and supporting precise risk assessment of heart diseases.
In June 2024, Thermo Fisher Scientific entered an agreement to collaborate with several North American hospital networks to pilot its advanced genetic testing reagent kits, aiming to accelerate adoption of personalized medicine across the region.
Press Releases